NCT07526545Recruiting
Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial
UPRISE (Urine Prostate Screening Integrated With MRI for Prostate Cancer Early Detection)
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- First submitted
- 6 Apr 2026
- Start date
- 1 Dec 2026
- Primary completion date
- 1 Jun 2030
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Diseases
- Prostate cancer
- NCT number
- NCT07526545
What you commit to
- Study type: Interventional
- Planned participants: 800
- From 1 Dec 2026 to the primary completion date, 1 Jun 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior diagnosis of prostate cancer
- Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work
Other
- Contraindication to MRI (e.g. claustrophobia, pacemaker)
- Contraindication to prostate biopsy
Who the study is looking for
- Males aged 50-75
- PSA 3-20 ng/ml within the previous 3 months
- Fit to undergo all procedures listed in protocol per treating physician's discretion
- No prostate biopsy in the past 4 years
- No prostate MRI in the past 2 years
- Able to provide written informed consent
Age in the registry: 50 years to 75 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Rogel Cancer Center Coordinator of this site? Confirm its status | Ann Arbor | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.